Read more

January 09, 2025
1 min read
Save

FDA clears Epithelial Thickness Module for Anterion imaging platform

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Key takeaways:

  • The Epithelial Thickness Module adds advanced thickness mapping and data insights.
  • Ectasia View is also available and offers tracking of ectatic changes in the cornea.

The FDA cleared the Epithelial Thickness Module for the Anterion cornea app from Heidelberg Engineering, according to a press release.

“Anterion technology stands out in the global market by offering the most data points and, consequently, the lowest level of data interpolation in representing epithelial thickness, setting it apart from other commercial devices,” Ram Liebenthal, general manager of Heidelberg Engineering USA, told Healio. “Emerging research indicates that the Epithelial Thickness Module could play a crucial role in detecting and managing corneal ectasias, highlighting its clinical relevance.”

Ram Liebenthal

As Healio previously reported, Anterion is an imaging platform that offers biometry, IOL power calculation, corneal topography and tomography, anterior chamber metrics and high-resolution swept-source OCT imaging. The Epithelial Thickness Module adds advanced thickness mapping, data insights, detailed parameters and color maps to the platform to evaluate the cornea’s epithelial and stromal structures, according to the release.

Heidelberg also announced that the Anterion now includes Ectasia View, which allows eye care professionals to track ectatic changes in the cornea by streamlining corneal data from multiple visits into a single dashboard.

The Epithelial Thickness Module will be commercially available in February, according to the release.

“Peer-reviewed publications often demonstrate that Anterion’s performance is not only equivalent but in some cases superior to current methods,” Liebenthal said. “Furthermore, it is the only device on the market equipped with live eye tracking, ensuring high repeatability and enhancing clinical confidence.”